Breaking News Instant updates and real-time market news.

PCRX

Pacira

$47.75

-1.3 (-2.65%)

, HRTX

Heron Therapeutics

$31.18

-0.47 (-1.49%)

07:35
10/02/18
10/02
07:35
10/02/18
07:35

Pacira price target raised to $49 from $45 at Canaccord

Canaccord analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (PCRX) and raised his price target to $49 from $45. Recently reported IQVIA monthly data for August show a major acceleration of volume and revenue growth vs. a year ago as well as substantial alignment in growth trends with Symphony Health data, Steadman tells investors in a research note. Longer term, however, he remains concerned about the potential advent of competition from Heron's (HRTX) HTX-011 with what some consider to be a superior clinical data set to Exparel, and expects Pacira shares could be rangebound for the near future following strong recent performance.

PCRX

Pacira

$47.75

-1.3 (-2.65%)

HRTX

Heron Therapeutics

$31.18

-0.47 (-1.49%)

  • 07

    Nov

PCRX Pacira
$47.75

-1.3 (-2.65%)

08/06/18
BOFA
08/06/18
DOWNGRADE
Target $46
BOFA
Neutral
Pacira downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded Pacira to Neutral from Buy and raised its price target to $46 from $39 following the Q2 beat. Analyst Tazeen Ahmad said shares now reflect 20%+ annual growth and are fully valued.
08/06/18
WEDB
08/06/18
NO CHANGE
Target $85
WEDB
Outperform
Pacira price target raised to $85 from $80 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Pacira to $85 from $80 after the company delivered better than expected Q2 earnings and revenue and raised EXPAREL net product sales full-year guidance from $300M-$310M to $320M-$325M. The analyst reiterates an Outperform rating on the shares.
09/13/18
STFL
09/13/18
INITIATION
Target $41
STFL
Sell
Pacira initiated with a Sell at Stifel
Stifel analyst Derek Archila initiated Pacira (PCRX) with a Sell rating and a price target of $41, saying the stock price is not "particularly cheap" following the rally driven by an upward revision to Exparel sales guidance during its Q2 earnings call. The analyst adds that the approval of Heron's (HRTX) HTX-011 also creates a "medium- to long-term headwind" for Pacira.
09/19/18
RBCM
09/19/18
NO CHANGE
Target $55
RBCM
Outperform
Pacira price target raised to $55 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira to $55 and kept his Buy rating after meeting with its management, saying the discussion gave him more confidence about the company's continued profitability momentum and more tailwinds coming in 2019. The analyst cites Pacira's efforts to achieve a broader label for EXPAREL, expansion of its r Ambulatory Surgery Center presence, and the confidence that it will "receive a J-code for EXPAREL" on January 1st.
HRTX Heron Therapeutics
$31.18

-0.47 (-1.49%)

07/26/18
JANY
07/26/18
NO CHANGE
Target $27
JANY
Sell
Pacira move higher not justified by CMS news, says Janney Montgomery Scott
Janney Montgomery Scott analyst Ken Trbovich attributed Pacira's (PCRX) 10% advance today to news that the Centers for Medicare and Medicaid Services is proposing to unbundle, and therefore pay separately, for non-opioid pain management drugs used in a covered surgery in an ambulatory surgery center. Quantifying the impact is difficult and while a change in the payment system would undoubtedly eliminate some concerns, it does not appear the upside justifies today's move, according to Trbovich. He also thinks any benefit Pacira may see "pales by comparison" to the 2-3 years of coverage Heron Therapeutics' (HRTX) HTX-011 is likely to receive under pass through payment provisions if approved by the FDA next year, said Trbovich. The analyst reiterates his Sell rating on Pacira, even though he thinks the company is likely to raise guidance when it reports earnings before the open on Aug. 2.
09/13/18
STFL
09/13/18
INITIATION
Target $55
STFL
Buy
Heron Therapeutics initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Heron Therapeutics with a Buy rating and a price target of $55. The analyst expects the company's HTX-011 to be approved for the prevention of postsurgical pain, becoming "the first product to receive an opioid sparing indication from the FDA". Archila adds that shares could be driven higher amid the "continued discussion about potential legislation to unbundle branded non-opioid analgesic".
09/21/18
CANT
09/21/18
NO CHANGE
Target $50
CANT
Overweight
Heron Therapeutics selloff not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes sees no fundamental reason for the recent weakness in shares of Heron Therapeutics. The pullback provides a "compelling entry point," Folkes tells investors in a research note. He believes the market opportunity for HTX-011 "remains compelling," with peak sales potential of over $1B. The analyst reiterates an Overweight rating on Heron with a $50 price target.

TODAY'S FREE FLY STORIES

TXT

Textron

$49.19

0.76 (1.57%)

06:33
01/24/19
01/24
06:33
01/24/19
06:33
Hot Stocks
Textron CEO says 'strong execution in both the quarter and full year' »

"We had strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TXT

Textron

$49.19

0.76 (1.57%)

06:32
01/24/19
01/24
06:32
01/24/19
06:32
Earnings
Textron sees FY19 cont ops EPS $3.55-$3.75, consensus $3.49 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AIT

Applied Industrial Technologies

$60.36

-1.34 (-2.17%)

06:31
01/24/19
01/24
06:31
01/24/19
06:31
Earnings
Applied Industrial Technologies reports Q2 EPS 99c, consensus $1.06 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TXT

Textron

$49.19

0.76 (1.57%)

06:30
01/24/19
01/24
06:30
01/24/19
06:30
Earnings
Textron reports Q4 cont ops EPS $1.15, consensus 98c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TCEHY

Tencent

$0.00

(0.00%)

, KKR

KKR

$22.28

0.12 (0.54%)

06:29
01/24/19
01/24
06:29
01/24/19
06:29
Periodicals
Tencent, buyout firms mull offers for Nexon stake, Bloomberg reports »

Tencent Holdings (TCEHY)…

TCEHY

Tencent

$0.00

(0.00%)

KKR

KKR

$22.28

0.12 (0.54%)

NEXOF

Nexon

$0.00

(0.00%)

BX

Blackstone

$32.36

-0.24 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 01

    Feb

  • 11

    Feb

KRA

Kraton

$25.50

-0.77 (-2.93%)

06:26
01/24/19
01/24
06:26
01/24/19
06:26
Recommendations
Kraton analyst commentary  »

Kraton shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCMLY

LafargeHolcim

$0.00

(0.00%)

06:25
01/24/19
01/24
06:25
01/24/19
06:25
Downgrade
LafargeHolcim rating change  »

LafargeHolcim downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESSYY

Essity

$0.00

(0.00%)

06:23
01/24/19
01/24
06:23
01/24/19
06:23
Initiation
Essity initiated  »

Essity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$8.03

0.3 (3.88%)

06:23
01/24/19
01/24
06:23
01/24/19
06:23
Periodicals
PG&E says wildfire prevention may cost up to $150B, Reuters reports »

PG&E, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONXXF

Ontex Group

$0.00

(0.00%)

06:21
01/24/19
01/24
06:21
01/24/19
06:21
Initiation
Ontex Group initiated  »

Ontex Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

06:20
01/24/19
01/24
06:20
01/24/19
06:20
Periodicals
Google to appeal $57M fine for breaching GDPR rules, Business Insider reports »

Google has confirmed it…

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

AAPL

Apple

$153.91

0.61 (0.40%)

, SSNLF

Samsung

$0.00

(0.00%)

06:18
01/24/19
01/24
06:18
01/24/19
06:18
Periodicals
Samsung exec poached by Apple to lead battery development, Bloomberg reports »

Apple (AAPL) has poached…

AAPL

Apple

$153.91

0.61 (0.40%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

EADSY

Airbus

$0.00

(0.00%)

06:14
01/24/19
01/24
06:14
01/24/19
06:14
Periodicals
Airbus CEO issues warning about jobs in event of no-deal Brexit, Reuters reports »

Airbus CEO Tom Enders…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$30.55

1 (3.38%)

06:11
01/24/19
01/24
06:11
01/24/19
06:11
Periodicals
Sinclair Broadcast hires liberal commentator Ameshia Cross, WSJ reports »

Sinclair Broadcast, known…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$91.51

-0.13 (-0.14%)

06:10
01/24/19
01/24
06:10
01/24/19
06:10
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.22

-0.18 (-1.17%)

06:08
01/24/19
01/24
06:08
01/24/19
06:08
Downgrade
CenturyLink rating change  »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 25

    Feb

ASND

Ascendis Pharma

$73.16

-0.47 (-0.64%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Ascendis Pharma rating change  »

Ascendis Pharma upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Recommendations
F5 Networks analyst commentary  »

F5 Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTH

Duluth Holdings

$20.41

0.425 (2.13%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Duluth Holdings rating change  »

Duluth Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:06
01/24/19
01/24
06:06
01/24/19
06:06
Hot Stocks
Nissan plans April investor meeting to oust Ghosn from board »

Nissan (NSANY) announced…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

, BDRBF

Bombardier

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Hot Stocks
Bombardier to acquire Global 7500 aircraft wing program from Triumph Group »

Bombardier (BDRBF)…

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

BDRBF

Bombardier

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

RNSDF

Renault

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Periodicals
Renault's board asked to name Senard, Bollare to replace Ghosn, Reuters says »

Renault's board will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.04

0.195 (2.20%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Periodicals
Deutsche Bank gets inquiry from House panels on Trump ties, Reuters reports »

Deutsche Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$99.46

-1.16 (-1.15%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Downgrade
Post Holdings rating change  »

Post Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 01

    Feb

MTL

Mechel

$2.50

0.075 (3.10%)

06:01
01/24/19
01/24
06:01
01/24/19
06:01
Hot Stocks
Mechel launches steel trade online store »

Mechel reports launching…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.